[HTML][HTML] Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action
MD Pescovitz - American journal of transplantation, 2006 - Elsevier
Rituximab, chimeric anti-human CD20, is approved for treatment of B-cell lymphoma in
adults. It is being used experimentally in other various immune-related diseases such as
immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and
rheumatoid arthritis. In transplant recipients, it is used for treatment of post-transplant
lymphoproliferative disease, to anecdotally reduce pre-formed anti-HLA and anti-ABO
antibodies and for the prevention and treatment of acute rejection. This article primarily …
adults. It is being used experimentally in other various immune-related diseases such as
immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and
rheumatoid arthritis. In transplant recipients, it is used for treatment of post-transplant
lymphoproliferative disease, to anecdotally reduce pre-formed anti-HLA and anti-ABO
antibodies and for the prevention and treatment of acute rejection. This article primarily …